Document:

PRODUCT FORMULA AGREEMENT

                  PRODUCT FORMULA AGREEMENT, dated as of this 5th day of
January, 2001 by and between SafeScience, Inc., a Nevada corporation with its
offices in Boston, MA ("SafeScience") and Delta-Omega Technologies, Inc., a
Colorado corporation (the "Company") with its offices in Broussard, LA.

                  WHEREAS, the Company has developed certain proprietary
formulations for cleaning products; and

                  WHEREAS, SafeScience is interested in acquiring title to
certain of these formulations and acquiring certain first refusal rights to
certain other of these formulations from the Company; and

                  WHEREAS, SafeScience is willing to make payments to the
Company in consideration of its transfer of the formulations being acquired and
its grant of certain first refusal rights hereunder to other formulations; and

                  WHEREAS, the Company is willing to grant to SafeScience title
to certain formulations and to grant certain first refusal rights as set forth
herein.

                  NOW THEREFORE, in consideration of the foregoing, the parties
agree as follows:

1.       Transfer of Existing SafeScience Consumer Cleaning Formulas.

         (a) The Company hereby grants all its rights, title and interest to the
consumer cleaning formulas listed on Exhibit A, and all instructions,
procedures, know-how and other information necessary for the manufacture thereof
(collectively, the "SafeScience Consumer Cleaning Formulas") to SafeScience,
including all modifications, enhancements and improvements thereto to date.

         (b) So long as SafeScience is not in violation of its royalty payment
obligations under paragraph 2(b), the Company shall not produce, create or
license to or for itself or any third party any formulation for any cleaning
product that is sold competitively with the cleaning products produced from the
SafeScience Consumer Cleaning Formulas as listed on Exhibit A.

2.       Payments by SafeScience.  SafeScience shall make the following payments
to the Company:

         (a)      $50,000 on the date hereof
                  $50,000 on April 1, 2001

         (b) 2% of net sales for all products produced from the SafeScience
Consumer Cleaning Formulas from the date hereof through January 5, 2005. Such
payments shall be made on a quarterly basis within 30 days of the end of each
calendar quarter. Net sales are defined as gross sales actually invoiced less
returns, cash discounts and necessary trade

<PAGE>

allowance and less separately invoiced amounts such as taxes, shipping and
insurance.

         (c) The parties agree that the payments due under Section 2(b) above
shall be initially offset by the amounts due to SafeScience by the Company
pursuant to the purchase order #s 42848, 42849, 42818, 42816, 42830, 42840,
42838, 42834, 42832, 42836, 42841, 42814, 42819, 9789, 42817, 9960 and 42843 for
S.S. 3000 dated from August 10, 2000 through October 27, 2000.

3.       Rights to SafeScience Industrial Products. The Company grants
SafeScience the first right, prior to all other third parties, to negotiate an
exclusive worldwide license to make, manufacture, sell and distribute each of
the industrial cleaning products developed specifically for SafeScience listed
in Exhibit B (collectively, the "SafeScience Industrial Products") on
substantially similar terms as the draft Exclusive Supply and License Agreement
dated January 27, 2000 attached as Exhibit C. SafeScience's first right to
negotiate an exclusive worldwide license shall not be subject to the receipt by
the Company of any offer to license the SafeScience Industrial Products. If the
Company receives an offer to license all or some of the SafeScience Industrial
Products it shall promptly notify SafeScience and negotiate in good faith to
license such SafeScience Industrial Products to SafeScience on substantially
similar terms as the draft Exclusive Supply and License Agreement dated January
27, 2000, except for pricing which shall meet the new offer.

4.       Forgiveness of Loan. SafeScience hereby agrees to forgive the
outstanding principal balance and interest due thereon of the Company's
promissory note to SafeScience dated May 14, 1999.

5.       New Consumer Formulas.

         (a) If the Company creates or produces any formulas for new consumer
cleaning products requested by SafeScience and agreed upon by the Company, after
the date hereof ("New Consumer Formulas") the Company shall license the New
Consumer Formulas to SafeScience on substantially similar terms, including
exclusivity, term and license fee, as the Exclusive License Agreement between
the Company and SafeScience dated September 15, 1999.

         (b) SafeScience shall have the option to purchase the New Consumer
Formulas for the initial purchase price for each New Consumer Formula of
$20,000, payable in advance plus 2% of net sales for all products produced from
such New Consumer Formula for a period of four (4) years from the date of
purchase of such New Consumer Formula (the "New Consumer Formula Purchase
Price"), and such New Consumer Formula shall be considered a SafeScience
Consumer Cleaning Formula for the purpose of this Product Formula Agreement. The
initial base price of $20,000 shall be increased each year based on the consumer
Price Index as published in the Wall Street Journal on the date nearest the
anniversary of this agreement. Net sales shall have the same definition as in
Section 2(b) hereof. SafeScience shall exercise its option to purchase any or
all New Consumer Formulas by delivering written notice to the Company.
SafeScience and the Company shall negotiate in good faith and complete the
purchase of such New Consumer Formulas

                                      -2-

<PAGE>

within forty-five (45) days of SafeScience's notice to exercise its option.

         (c) The Company can request SafeScience to exercise its option to
purchase a New Consumer Formula pursuant to section 5(b) by giving written
notice of the Company's intent to find a potential third party buyer of a New
Consumer Formula. If SafeScience does not notify the Company of its intent to
exercise its option pursuant to Section 5(b) within 10 (ten) business days of
receipt of the Company's request, then the Company may seek to sell the New
Consumer Formula pursuant to this Section 5(c) notwithstanding paragraph 1(b).
In the event the Company seeks to sell any New Consumer Formula, the Company
shall notify SafeScience in writing of the terms of such sale at least thirty
(30) calendar days prior to the date of such sale (the "Offer Notice"). Upon
receipt of the Offer Notice, SafeScience shall have twenty (20) days to exercise
a right of first refusal to enter into an agreement to purchase all or some of
the New Consumer Formulas covered by the Offer Notice for the greater of the New
Consumer Formula Purchase Price or the amount offered by any third party prior
to the offer notice. If SafeScience fails to notify the Company in writing
within said twenty (20) day period of its election to exercise its right of
first refusal, SafeScience shall be deemed to have waived all such rights and
the Company may conclude the sale to a third party notwithstanding paragraph
1(b).

         If SafeScience does not exercise its right of first refusal, the
Company may enter into such sale only on the terms (including the date)
described in, and with the party identified in, the Offer Notice. If the Company
has not entered into such sale pursuant to the Offer Notice within ninety (90)
days after the Offer Notice, then the restrictions provided by this Section 5
shall again become effective.

6.       Improvements to Products.

         (a) The Company shall make such modifications, adjustments,
enhancements and/or improvements (collectively "Improvements") to the
SafeScience Consumer Cleaning Formulas as requested by SafeScience. SafeScience
shall have all right, title and interest to any such Improvements to the
SafeScience Consumer Cleaning Formulas. SafeScience shall pay the Company all
reasonable expenses incurred by the Company on a time and materials basis in
connection with Improvements to the SafeScience Consumer Cleaning Formulas.
Prior to beginning any Improvements to the SafeScience Consumer Cleaning
Formulas, the Company shall provide an estimate to SafeScience of its time and
material costs in connection with Improvements to the SafeScience Consumer
Cleaning Formulas.

         (b) The Company may continue to develop Improvements to the SafeScience
Industrial Products. Any Improvements on SafeScience Industrial Products shall
also be considered SafeScience Industrial Products for the purposes of this
Agreement and shall be subject to all provisions hereof.

7.       Rights Regarding Third Parties Manufacturers. The Company presently
manufactures industrial cleaning products, other than the SafeScience Industrial
Products, which are purchased from the Company by SafeScience and listed in
Exhibit D. The

                                      -3-
<PAGE>

Company agrees to negotiate in good faith to grant SafeScience the right to have
a third party manufacture such products if, as a result of the high volume of
demand which exceeds the Company's production capacity for any such products,
based on firm orders as verified by the Company, or quality control concerns
with respect to any such product, SafeScience determines in good faith that the
Company is unable to provide SafeScience with the necessary quantity or quality
of such products.

8.       Other Obligations.

         (a) The Company shall promptly grant to SafeScience 100,000 shares (the
"DOTK Shares") of its common stock par value $.001. The Company shall file a
registration statement covering the DOTK Shares within one hundred twenty (120)
days of the date hereof. Thereafter, the Company shall use its best efforts to
cause such registration statement to be declared effective by the 180th day
after the date hereof. The Company shall keep such registration statement
effective until SafeScience may sell the DOTK Shares without registration
pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended
("Rule 144").

         The Company may postpone the filing of any registration statement
required pursuant to this Section 8(a) for a reasonable period of time, not to
exceed sixty (60) days in the aggregate, and not more than once in any ninety
(90) day period, if the Company has been advised by legal counsel in writing,
with a copy to the undersigned upon their request, that such filing would
require a special audit or the disclosure of a material impending transaction or
other matter and the Board of Directors of the Company determines reasonably and
in good faith that such disclosure would have a material adverse effect on the
Company.

         The Company shall pay all expenses incurred by the Company in
connection with the registration, qualification and/or exemption of the DOTK
Shares, including any SEC and state securities law registration in the state of
Massachusetts, or other states where registration is required by law, and filing
fees, printing expenses, fees and disbursements of the Company's counsel and
accountants, transfer agents' and registrars' fees, fees and disbursements of
experts used by the Company in connection with such registration, qualification
and/or exemption, and expenses incidental to any amendment or supplement to the
registration statement or prospectuses contained therein. The Company shall not,
however, be liable for any sales, broker's or underwriting commissions upon sale
by the undersigned or other holder of any of the DOTK Shares.

         (b) SafeScience shall promptly grant to the Company such number of
shares (the "SAFS Shares") of its common stock, par value $0.01 as shall have a
value of $200,000 based on the Closing price of SafeScience's common stock on
the date hereof. SafeScience shall file a registration statement covering the
SAFS Shares within one hundred twenty (120) days of the date hereof. Thereafter,
SafeScience shall use its best efforts to cause such registration statement to
be declared effective by the 180th day after the date hereof. SafeScience shall
keep such registration statement effective until the Company may sell the SAFS
Shares without registration pursuant to Rule 144.

                                      -4-
<PAGE>

         SafeScience may postpone the filing of any registration statement
required pursuant to this Section 8(b) for a reasonable period of time, not to
exceed sixty (60) days in the aggregate, and not more than once in any ninety
(90) day period, if SafeScience has been advised by legal counsel in writing,
with a copy to the undersigned upon their request, that such filing would
require a special audit or the disclosure of a material impending transaction or
other matter and the Board of Directors of SafeScience determines reasonably and
in good faith that such disclosure would have a material adverse effect on
SafeScience.

         SafeScience shall pay all expenses incurred by SafeScience in
connection with the registration, qualification and/or exemption of the SAFS
Shares, including any SEC and state securities law registration in the State of
Louisiana, or other states where registration is required by law, and filing
fees, printing expenses, fees and disbursements of SafeScience's counsel and
accountants, transfer agents' and registrars' fees, fees and disbursements of
experts used by SafeScience in connection with such registration, qualification
and/or exemption, and expenses incidental to any amendment or supplement to the
registration statement or prospectuses contained therein. SafeScience shall not,
however, be liable for any sales, broker's or underwriting commissions upon sale
by the undersigned or other holder of any of the SAFS Shares.

9.       Right to Audit. SafeScience shall at all times through and until
January 5, 2005 keep true and correct books of account and maintain documents
(including where appropriate documents produced by third party manufacturers and
provided to SafeScience) which show the payments due pursuant to Section 2(b) to
which the Company is entitled. The books of account and documentation shall be
retained by SafeScience through and until January 5, 2007 and shall be open to
inspection by an authorized representative of the Company, at the Company's
expense. Such inspections shall be carried out no more than twice per year,
during usual business hours of SafeScience by the Company or its assigns,
successors or representatives upon five (5) business days prior notice. In the
event an audit by the Company determines that SafeScience has underpaid the
payments due to the Company under Section 2(b) by more than 10% in any one-year
period, the expenses of the audit shall forthwith be reimbursed by SafeScience
to the Company.

10.      Confidentiality and Non-Disclosure of Information.

         (a) As used in this Agreement, the term "Confidential Information"
means confidential or proprietary technical or business information furnished by
one party to the other party in connection with this Agreement, regardless of
whether such information is in written, oral, electronic, or other tangible
form. Such Confidential Information may include, without limitation, trade
secrets, know-how, inventions, technical data or specifications, testing
methods, business or financial information, research and development activities,
product and marketing plans, and customer and supplier information. The
SafeScience Consumer Cleaning Formulas shall be the Confidential Information of
SafeScience and shall not be subject to exception (3) to Confidential
Information contained in Section 10(b) below.

                                      -5-
<PAGE>

         (b) Each party shall maintain the other party's Confidential
Information in confidence and shall not disclose such Confidential Information
to any third party without the prior written consent of the disclosing party and
shall not use such Confidential Information other than in furtherance of this
Agreement. The foregoing shall not apply to information that (1) is or hereafter
becomes generally available to the public other than by reason of any default
with respect to confidentiality under this Agreement; (2) is disclosed to such
party by a third party who is not in default of any confidentiality obligation
to the other party; (3) is developed by or on behalf of such party, without
reliance on confidential information acquired from the other party; (4) is
provided by such party under appropriate terms and conditions, including
confidentiality provisions equivalent to those in this Agreement, to third
parties for consulting, accounting, legal and similar purposes.

         (c) Each party shall limit access to the other party's Confidential
Information to those of its directors, officers, agents, employees, consultants
and advisors who have a need to know and who have been informed in writing of
and agreed to be bound by the obligations of confidentiality imposed by this
Agreement. Each party shall allow its directors, officers, agents, employees,
consultants, and advisors to reproduce the Confidential Information only to the
extent necessary to effect the purposes set forth in this Agreement, with all
such reproductions being considered Confidential Information. The receiving
party shall cause its directors, officers, agents, employees, consultants and
advisors to keep in confidence the Confidential Information consistent with this
Agreement and shall be responsible for any disclosures by such persons not
permitted hereunder.

         (d) In the event a party shall be required to disclose any Confidential
Information (a "Compelled Party"), it will give the other party prompt notice of
such requirement so that the other party may seek a protective order or other
appropriate remedy. Unless the requirement shall have been timely limited,
quashed or extended, the Compelled Party shall thereafter be entitled to comply
with such demand to the extent required by law. If requested by the other party,
the Compelled Party shall cooperate (at the expense of the other party) in the
defense of a demand.

         (e) In the event of any breach by a party or any of its agents of the
provisions of this Section 10, the other party may, subject to the provisions of
Section 16(c), immediately seek injunctive relief in any court of competent
jurisdiction in addition to any other rights or remedies provided for herein.

11.      Infringement.

         (a) In the event that the Company learns of any infringement or
unauthorized use of the SafeScience Consumer Cleaning Formulas, it shall
promptly notify SafeScience. SafeScience shall have the sole initial right to
bring infringement actions or other similar proceedings against third parties in
order to protect the SafeScience Consumer Cleaning Formulas. If requested to do
so, the Company shall reasonably cooperate with SafeScience in any such action,
including but not limited to joining the action as a party if necessary to
maintain standing.

         (b) If SafeScience determines not to take any such action, then the
Company

                                      -6-
<PAGE>

may take such action in its own name. SafeScience may cooperate with the Company
or join such action at its sole discretion. In the event such an action taken by
the Company is successful and the Company is not awarded all its costs and
expenses (including attorney's fees) incurred in connection with the prosecution
thereof, then SafeScience agrees to participate in and contribute to the costs
and expenses of such prosecution in ratable proportion to the relative losses to
the parties incurred as a result of the infringing conduct. The relative losses
of the parties shall be determined based upon, in the case of SafeScience,
SafeScience's estimated gross profits from the sales lost as a result of the
infringement, and in the case of the Company, on the Section 2(b) fees that
would have been payable on the sales lost as a result of the infringement.

         (c) Any award recovered by the Company or SafeScience in any action or
proceeding commenced by it as under this Section 11 shall be divided between the
parties as follows: first, to both parties of their respective, actual
out-of-pocket costs (which amount shall be allocated pro rata if the amount
recovered is less than the total amount of such costs); second, any amounts
awarded in respect of lost sales or profits shall be allocated so as to
approximate, to the best of the parties' ability, to the Company the portion
thereof that represents the fees payable under Section 2(b) that would have been
payable with respect to such lost sales or profits, and to SafeScience the
balance of the amount so awarded.

12.      Indemnification.

         (a) The Company agrees and covenants to hold harmless and indemnify and
defend SafeScience, its subsidiaries, affiliates, officers, directors,
employees, agents and assigns, from and against any suits, actions, claims,
losses, demands, liabilities, costs and expenses of any kind, including costs
and attorneys' fees for defending the same, which may arise or result from any
claims of infringement by, or piracy of, the SafeScience Consumer Cleaning
Formulas, except to the extent caused by SafeScience's (or any of SafeScience's
agent's or third party manufacturer's) misuse, unauthorized modification of
SafeScience Consumer Cleaning Formulas or mislabeling.

         (b) SafeScience agrees and covenants to hold harmless and indemnify and
defend the Company, its subsidiaries, affiliates, officers, directors,
employees, agents and assigns (each a "Company Indemnified Party"), from and
against any suits, actions, claims, losses, demands, damages, liabilities, costs
and expenses of any kind, including costs and attorneys' fees for defending the
same, which may arise or result from SafeScience's use of the SafeScience
Consumer Cleaning Formulas, to the extent SafeScience's or its agents' actions
constitute breach of contract, negligence or willful misconduct toward a party
other than a Company Indemnified Party.

13.      Warranties. The Company represents and warrants to SafeScience that
(i) it has all corporate power and authority to grant its right, title and
interest in the SafeScience Consumer Cleaning Formula to SafeScience, (ii) the
execution and delivery of this Agreement and the transactions contemplated
hereby have been duly authorized by all necessary corporate action on the
Company's part, (iii) the SafeScience Consumer Cleaning Formulas do not
constitute substantially all the assets of the Company, (iv) to its

                                      -7-
<PAGE>

knowledge and belief the SafeScience Consumer Cleaning Formulas do not infringe
or violate any intellectual property rights of any third party, and no third
party has infringed upon the rights of the Company in the SafeScience Consumer
Cleaning Formulas, and (v) it has full right and title to the SafeScience
Consumer Cleaning Formulas.

14.      Termination.

         (a) Notwithstanding anything otherwise contained in this Agreement, the
Company shall have the right to terminate the rights granted to SafeScience
hereunder (other than the Company's granting of its right, title and interest in
the SafeScience Consumer Cleaning Formulas to SafeScience) upon thirty (30) days
written notice to SafeScience (unless a longer period is set forth hereinbelow),
if SafeScience fails or refuses to pay promptly any amount payable under Section
2 when and as same shall become due and payable, and such default shall continue
for a period of thirty (30) days after written notice thereof has been given by
the Company to SafeScience; provided, however, (1) if SafeScience, within said
notice period, cures or otherwise terminates any of said events, said rights
shall continue on in force as if said notice had not been given, or (2) if
SafeScience, within said notice period, contests in good faith the veracity of
any of said events, said rights shall continue on in force until such time as
the veracity of said events shall be established by a final trier of fact, from
which no further appeal may be taken in accordance with Section 16(c).

         (b) SafeScience may terminate this Agreement at any time, for any
reason, upon thirty (30) days' notice thereof to the Company.

15.      Effect of Termination. Upon the termination of this Agreement, all
rights of SafeScience under Sections 3, 5, 6 and 7 shall cease forthwith and
shall immediately be null and void and thereafter SafeScience shall cease using
the SafeScience Industrial Products. Each party shall forthwith deliver to the
other party all forms, procedures, documents, copies of formulations, and other
Confidential Information of the other party. Section 2, 4, 8, 9, 10, 11, 12 and
13 shall survive any termination of this Agreement.

16.      General Provisions.

         (a) Relationship of Parties. No partnership, joint venture, employment,
agency or other relationship is formed, intended, or to be inferred under this
Agreement. Neither party to this Agreement shall make or authorize any
representation to the contrary.

         (b) Survival of Remedies. During and after the term of this Agreement,
each party shall be entitled to all rights, remedies and protections available
at law and in equity. The parties recognize that irreparable injury may result
to its business and property if the other party breaches any of the terms of
this Agreement, and each party agrees that if it engages in any act in violation
of this Agreement, the other party shall be entitled, in addition to such other
remedies and damages as may be available, to seek equitable relief including
injunction prohibiting the breaching party from engaging in such act and
specific performance.

                                      -8-
<PAGE>

         (c) Disputes. Should a dispute arise relative to the terms or
conditions of this Agreement, the parties shall, prior to commencing any
litigation or similar proceeding, engage in non-binding mediation with a
mediator mutually acceptable to the parties. In the event such mediation is
unsuccessful in resolving the dispute, the parties shall submit the dispute to
binding arbitration in Boston, Massachusetts pursuant to the rules then
prevailing of the American Arbitration Association. Any award made through the
arbitration shall be enforceable in any court of competent jurisdiction pursuant
to uniform laws regarding arbitration and the award may include an award of
attorney's fees and costs to the prevailing party. The foregoing arbitration
clause shall not be deemed to limit the right of either party to seek immediate
equitable relief, where permitted pursuant to applicable law or to the terms of
this Agreement, in a court of competent jurisdiction pending the arbitration
proceedings.

         (d) Waiver. The failure of either party to take any action under this
Agreement, or the waiver of a breach of this Agreement, shall not affect that
party's rights to require performance hereunder or constitute a waiver of any
subsequent breach.

         (e) Notice. All notices required or permitted to be given or made under
this Agreement must be made in writing and delivered by certified mail, return
receipt requested. Mailed notices shall be addressed to the parties as their
addresses appear below, except that in the event written notice of a change of
address is made in accordance with this section, then such mailed notices shall
be addressed to the party in question at such new address.

If to Delta-Omega Technologies, Inc.:

119 Ida Road
Broussard, LA 70518
Attn:  James V. Janes, III
Telephone: (318) 837-3011
Fax: (318) 837-3037

With copies to:

Roger V. Davidson, Esq.
Ballard Spahr Andrews & Ingersoll, LLP
1225 17th Street, Suite 2300
Denver, CO 80202-5596
Telephone: (303) 299-7307
Fax: (303) 296-3956

If to SafeScience, Inc.:

31 St. James Avenue
Boston, MA 02116
Attn: Bradley J. Carver, President
Telephone: (617) 422-0674

                                      -9-
<PAGE>

Fax: (617) 422-0675

With copies to:

Cheryl Reicin, Esq.
McDermott, Will & Emery
50 Rockefeller Plaza
New York, NY
Telephone:  (212) 547-5400
Fax:  (212) 547-5444

         (f) Interpretation. This Agreement shall be governed by and interpreted
in accordance with the laws of The Commonwealth of Massachusetts. The headings
herein are for reference only and shall not define or limit the provisions
hereof.

         (g) Entire Agreement. This Agreement constitutes the entire agreement
between the parties with respect to the subject matter addressed herein, and all
prior and contemporaneous agreements, whether written or oral, as may relate to
the same, are hereby superseded by this Agreement.

         (h) Modification. This Agreement may not be altered, modified, amended
or changed, in whole or in part, except by a writing executed by the parties.

         (i) Successors. This Agreement shall be binding upon the parties and
their permitted assigns, corporate successors and representatives. Neither party
may assign this Agreement or its rights hereunder without the prior written
consent of the other party which shall not be unreasonably withheld, provided
such assignee agrees to assume the responsibilities and obligations of the
assigning party hereunder.

         (j) Attorneys' Fees. In the event of any dispute which results in a
suit or other legal proceeding to construe or enforce any provision of this
Agreement or because of an alleged breach, default or misrepresentation in
connection with any of the provisions of this Agreement, the parties agree that
the prevailing party or parties (in addition to all other amounts and relied to
with such party or parties may be entitled) shall be entitled to recover
reasonable attorneys' fees and other costs incurred in any action or proceeding.

         (k) Previous Agreement. This Agreement shall be deemed to supersede the
Exclusive License Agreement dated September 15, 1999 between SafeScience and the
Company and the Supply and Distribution Agreement dated July 8, 1998 between
SafeScience and the Company.

                  IN WITNESS WHEREOF, the parties have hereunto set their hands
and seals as of the date first above written.

SAFESCIENCE, INC.                   DELTA-OMEGA TECHNOLOGIES, INC.

By:  /s/ Bradley J. Carver          By: /s/ James V. Janes
     ---------------------              ----------------------------------------

                                      -10-
<PAGE>

Title:   Chief Executive Officer            Title:  Co-Chief Executive Officer

                                            By: /s/ Illegible
                                                --------------------------------

                                            Title:  Co-Chief Executive Officer

                                      -11-
<PAGE>

                                   EXHIBIT A
                                   ---------

                     SafeScience Consumer Cleaning Formulas

Product Name                                           SAFS Item Number
------------                                           ----------------

All Purpose RTU                                           301
Kitchen Cleaner                                           308
Window/Glass Cleaner RTU                                  304
Floor Cleaner RTU                                         303
Shower Mist                                               305
Bathroom Cleaner RTU                                      310
Dishwash RTU                                              302
Laundry Detergent                                         309
Exterior Home & Window                                    307
Citrus Scent All Purpose                                20024
All Purpose Mint                                        25003

<PAGE>

                                    EXHIBIT B
                                    ---------

                         SafeScience Industrial Products

Product Name                                                 SAFS Item Number
------------                                                 ----------------

Oven/Grill Heavy Duty Cleaner                                  315
Window/Glass Cleaner Concentrate                               314
Window/Glass Cleaner RTU                                       314
All Purpose Cleaner Concentrate                                310
All Purpose Cleaner RTU                                        310
Floor Cleaner Concentrate                                      313
Stain Remover                                                  318
Liquid Laundry                                                 319
Bathroom Cleaner Concentrate                                   317
Bathroom Cleaner RTU                                           317
Exterior Window/Glass Cleaner                                  320

<PAGE>

                                    EXHIBIT C
                                    ---------

<PAGE>

                                    EXHIBIT D
                                    ---------

                    Delta-Omega Industrial Cleaning Products

Product Name                                               SAFS Item Number
------------                                               ----------------

Carpet Shampoo                                                316
Concrete Cleaner                                              326
Multi-Clean Super Concentrate                                 323
Aircraft Wash HD                                              325
Aircraft Wash                                                 324
Wash n' Wax Concentrated Liquid                               321
Defoamer                                                   DF-100
D-Limonene    (OCY Industrial Clean                        SS2000
Intermediate (Glyco Ether)                                 SS3000
HazClean EFFF                                              SS3100THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT") OR ANY APPLICABLE STATE
SECURITIES LAW, AND MAY NOT BE TRANSFERRED EXCEPT (i) PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT OR (ii) UPON FIRST FURNISHING TO THE
COMPANY AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH TRANSFER IS
NOT IN VIOLATION OF THE REGISTRATION REQUIREMENTS OF THE ACT OR ANY APPLICABLE
STATE SECURITIES LAW.

                                 687,500 Shares

                              COMMON STOCK WARRANT

                   For the Purchase of Shares of Common Stock
                                       of
                                SafeScience, Inc.
                          -----------------------------

         THIS CERTIFIES THAT, for value received, Wayne State University (the
"Holder") or their registered assigns, are entitled to subscribe for and
purchase from SafeScience, Inc., a Nevada corporation (the "Company"), six
hundred eighty-seven thousand five hundred (687,500) fully paid and
non-assessable shares of the Company's Common Stock, par value $.01 per share
("Common Stock"), subject to the terms and conditions set forth herein at a
purchase price of $1.15 per share (the "Exercise Price"). This Warrant shall be
exercisable, subject the vesting requirements in Section 1, until January 26,
2011.

         1. Vesting. The shares of this Warrant shall vest 85,938 shares
quarterly over a period of two years, commencing March 31, 2001;
notwithstanding, however, that 85,934 shares shall vest in the eighth period.

         2. Exercise of Warrant. The rights represented by this Warrant may be
exercised by the holders hereof, in whole or in part (but not as to a fractional
share of Common Stock), by the surrender of this Warrant (with the notice of
exercise form attached hereto as Exhibit 1 (the "Notice of Exercise") duly
executed) at the office of any duly appointed transfer agent for the Common
Stock or at the principal office of the Company and upon payment to the Company,
or for the account of the Company, by cash or certified check or wire transfer,
of the purchase price for such shares in the amount equal to the product of (a)
the Exercise Price, times (b) the number of shares of Common Stock being
purchased.

         3. Delivery of Stock Certificates on Exercise. As soon as practicable
after the exercise of this Warrant in accordance with Section 2 hereof and in
any event within 10 days thereafter, the Company at its expense will cause to be
issued in the name of and delivered to the holder hereof, or as such holder
(upon payment by such holder of any applicable transfer taxes) may direct, a
certificate or certificates for the number of shares of Common Stock to which
such holder shall be entitled on such exercise, and, unless this Warrant has
expired or has been

<PAGE>

exercised in full, a new Warrant representing the number of shares with respect
to which this Warrant shall not then have been exercised shall also be issued to
the holder hereof at such time. The Holders of this Warrant acknowledges that
the certificate or certificates representing the shares of stock issuable upon
the exercise of this Warrant shall be stamped or otherwise imprinted with a
legend substantially in the following form:

                  "The securities represented by this certificate have not been
              registered under the Securities Act of 1933, as amended, or the
              securities laws of any state. The securities have been acquired
              for investment and may not be sold, offered for sale or
              transferred in the absence of an effective registration under the
              Securities Act of 1933, as amended, and any applicable state
              securities laws or an opinion of counsel satisfactory in form and
              substance to counsel for the Company that the transaction shall
              not result in a violation of state or federal securities laws."

         Upon the request of a holder of a certificate representing shares of
Common Stock purchased upon exercise of this Warrant, the Company shall remove
the foregoing legend from the certificate or issue to such holder a new
certificate therefor free of any transfer legend, if, with such request, the
Company shall have received an opinion of counsel reasonably satisfactory to the
Company to the effect that such legend may be removed from such certificate.

         4. Shares to be Issued, Reservation of Shares; Holders of Record.

              (a) Shares to be Issued. The Company covenants and agrees that all
shares which may be issued upon the exercise of the rights represented by this
Warrant will, upon issuance, be validly authorized, issued and outstanding,
fully paid and non-assessable, and free from all taxes, liens and charges with
respect to the issue thereof.

              (b) Reservation of Common Stock. The Company covenants and agrees
that, during the period within which the rights represented by this Warrant may
be exercised, the Company will at all times have authorized and reserved a
sufficient number of shares of its Common Stock to provide for the exercise of
the rights represented by this Warrant.

              (c) Holders of Record. Each person or entity in whose name any
certificate for shares of Common Stock is issued upon the exercise of this
Warrant in accordance with its terms shall for all purposes be deemed to have
become the holder of record of the shares of Common Stock represented thereby
on, and such certificate shall be dated, the date upon which the Notice of
Exercise was duly executed and payment of the aggregate Exercise Price was made
pursuant to Section 2 hereof. Prior to the exercise of this Warrant, the holder
hereof shall not be entitled to any rights of a stockholder of the Company with
respect to the shares of Common Stock for which this Warrant shall be
exercisable, including, without limitation, the right to vote, to receive
dividends or other distributions or to exercise any preemptive rights and shall
not be entitled to receive any notice of any proceedings of the Company, except
as provided herein.

         5. Adjustment of Exercise Price. The Exercise Price in effect from time
to time shall be subject to adjustment as follows:

              (a) Adjustment for Common Stock Dividends; Subdivisions and
Combinations.

                                      -2-
<PAGE>

Upon the issuance of additional shares of Common Stock as a dividend or other
distribution on outstanding Common Stock, the subdivision of outstanding shares
of Common Stock into a greater number of shares of Common Stock, or the
combination of outstanding shares of Common Stock into a smaller number of
shares of the Common Stock, the number of shares of Common Stock purchasable
hereunder shall be proportionately adjusted to the nearest whole share and the
Exercise Price shall be proportionately decreased in the case of a dividend,
split or subdivision and proportionately increased in the case of a combination.
An adjustment made pursuant to this Section 5(a) shall be given effect, upon
payment of such a dividend or distribution, as of the record date for the
determination of stockholders entitled to receive such dividend or distribution
(on a retroactive basis) and in the case of a subdivision or combination shall
become effective immediately as of the effective date thereof.

              (b) Adjustments for Capital Reorganizations. If any capital
reorganization or reclassification of the capital stock of the Company shall be
effected, whether by merger, consolidation, sale of assets or otherwise (other
than a subdivision or combination of shares or stock dividend as provided for
above) (in each case, a "Reorganization"), then, as a condition of such
Reorganization, lawful and adequate provision shall be made whereby the holder
hereof shall thereafter have the right to purchase and receive upon the basis
and upon the terms and conditions specified in this Warrant, in lieu of shares
of Common Stock of the Company immediately theretofore purchasable and
receivable upon the exercise of the rights represented hereby, those shares of
stock, securities or assets which would have been issued or payable with respect
to or in exchange for the Common Stock issuable upon exercise of this Warrant
had this Warrant been exercised immediately prior to the record date (or the
effective date, as the case may be) for such Reorganization. Upon any
Reorganization this Warrant shall continue in full force and effect and the
terms hereof shall be applicable to the shares and other securities and property
receivable on the exercise of this Warrant after the consummation of such
Reorganization and shall be binding upon the issuer of any such stock or other
securities, including the person acquiring all or substantially all of the
properties or assets of the Company, whether or not such person shall have
expressly assumed the terms of this Warrant.

              (c) Other Adjustments. In the event the Company shall make or
issue, or fix a record date for the determination of holders of Common Stock
entitled to receive, a dividend or other distribution payable in securities of
the Company other than shares of Common Stock, then and in each such event
lawful and adequate provision shall be made so that the holders of Warrants
shall receive upon exercise thereof in addition to the number of shares of
Common Stock receivable thereupon, the number of securities of the Company which
such holders would have received had such Warrants been exercised on the date of
such event and had such holders thereafter, during the period from the date of
such event to and including the date of exercise, retained such securities
receivable by such holders as aforesaid during such period, giving application
to all adjustments called for during such period under this Section 5 as applied
to such distributed securities.

              (d) Notices of Adjustments. In each case of an adjustment pursuant
to this Section 5, the Company, at its expense, will furnish the holder of this
Warrant with a certificate, prepared by the chief financial officer of the
Company, showing such adjustment or readjustment, and the number of shares of
Common Stock or other securities and the amount, if any, of other property that
at the time would be received upon the exercise of this Warrant.

                                      -3-
<PAGE>

              (e) Notices of Record Date. In the event (i) the Company
establishes a record date to determine the holders of any class of securities
who are entitled to receive any dividend or other distribution or (ii) there
occurs any capital reorganization of the Company, any reclassification or
recapitalization of the capital stock of the Company, any merger or
consolidation of the Company, any acquisition of the Company, any transfer of
all or substantially all of the assets of the Company to any other Company
entity or person, any sale of a majority of the voting securities of the Company
in one or a series of related transactions or any voluntary or involuntary
dissolution, liquidation or winding up of the Company, the Company shall give to
the holder hereof a notice specifying (a) the date of such record date for the
purpose of such dividend or distribution and a description of such dividend or
distribution, (b) the date on which any such reorganization, reclassification,
transfer, consolidation, merger, acquisition, sale, dissolution, liquidation or
winding up is expected to become effective, and (c) the time, if any, that is to
be fixed, as to when the holders of record of Common Stock (or other securities)
shall be entitled to exchange their shares of Common Stock (or other securities)
for securities or other property deliverable upon such reorganization,
reclassification, transfer, consolidation, merger, acquisition, sale,
dissolution, liquidation or winding up. Such written notice shall be given to
the holder of this Warrant at least fifteen (15) days prior to the date
specified in such notice on which any such action is to be taken.

         6. Holder Representations and Warranties. The Holder of this Warrant
understands the risks of investing in emerging companies such as the Company and
can afford a loss of its entire investment. The Holder is acquiring the Warrant
for investment and not with the view to, or for resale in connection with, any
distribution thereof. The Holder understands that the Warrant and the shares of
Common Stock issuable upon exercise thereof have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"), or any applicable
state securities ("blue sky") laws, by reason of specified exemptions from the
registration provisions of the Securities Act and such laws. The Holder
acknowledges that the Warrant and the shares of Common Stock issuable upon
exercise thereof must be held indefinitely unless they are subsequently
registered under the Securities Act or an exemption from such registration is
available. The Holder hereof has been advised or is aware of the provisions of
Rule 144 promulgated under the Securities Act, which permits the resale of
shares purchased in a private placement subject to the satisfaction of certain
conditions and that such Rule may not be available for resale of the shares.

         7. Transfer. Subject to compliance with applicable securities laws,
this Warrant and all rights hereunder are transferable, in whole or in part, at
the offices referred to in paragraph 2 hereof by the holder in person or by a
duly authorized attorney, upon surrender of this Warrant properly endorsed. Each
taker and holder of this Warrant, by taking or holding the same, consents and
agrees that this Warrant, when endorsed in blank, shall be deemed negotiable and
that when this Warrant is so endorsed, the holder hereof may be treated by the
Company and all other persons dealing with this Warrant as the absolute owner
hereof for any purposes and as the person entitled to exercise the rights
represented by this Warrant or to the transfer hereof on the books of the
Company, any notice to the contrary notwithstanding; but until each transfer on
such books, the Company may treat the registered holder hereof as the owner
hereof for all purposes.

         8. Exchange. Subject to compliance with applicable securities laws,
this Warrant is

                                      -4-
<PAGE>

exchangeable, upon the surrender hereof by the holder hereof at such offices for
new Warrants of like tenor representing in the aggregate the right to subscribe
for and purchase the number of shares which may be subscribed for and purchased
hereunder, each of such new Warrants to represent the right to subscribe for and
purchase such number of shares as shall be designated by such holder hereof at
the time of such surrender. Upon receipt of evidence satisfactory to the Company
of the loss, theft, destruction or mutilation of this Warrant and, in the case
of any such loss, theft or destruction, upon delivery of a bond of indemnity
satisfactory to the Company, or, in the case of any such mutilation, upon
surrender or cancellation of this Warrant, the Company will issue to the holder
hereof a new Warrant of like tenor, in lieu of this Warrant, representing the
right to subscribe for and purchase the number of shares which may be subscribed
for and purchased hereunder.

         9. Registration Rights. The shares issuable upon exercise of this
Warrant shall have the registration rights described in Section 3.2(c) of the
License Agreement dated January 26, 2001 (the "License Agreement") by and among
the Company and the Holders. The Company may postpone the filing of any
registration statement required pursuant to the License Agreement for a
reasonable period of time, not to exceed sixty (60) days in the aggregate, and
not more than once in any ninety (90) day period, if the Company has been
advised by legal counsel in writing, with a copy to the undersigned upon their
request, that such filing would require a special audit or the disclosure of a
material impending transaction or other matter and the Board of Directors of the
Company determines reasonably and in good faith that such disclosure would have
a material adverse effect on the Company.

         10. Notices. Notices or demands relating to this Warrant shall be
sufficiently given or made if sent by prepaid air express courier with regular
service to the addressee, or telexed, telecopied or hand-delivered, if to the
Company, at the address of its principal office or if to the holder of this
Warrant, at its address registered on the books of the Company.

         11. No Impairment. The Company will not, by amendment of its Charter or
by any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good
faith assist in the carrying out of all such terms and in the taking of all such
action as may be necessary or appropriate in order to protect the rights of the
Holder of this Warrant against impairment.

         12. No Rights or Liabilities as a Stockholder. This Warrant shall not
entitle the Holders hereof to any voting rights or other rights as a stockholder
of the Company. No provision of this Warrant, in the absence of affirmative
action by the holder hereof to purchase Common Stock, and no mere enumeration
herein of the rights or privileges of the holder hereof, shall give rise to any
liability of such holder for the Exercise Price or as a stockholder of the
Company, whether such liability is asserted by the Company or by creditors of
the Company.

         13. Miscellaneous. The provisions of this Warrant may be amended or
waived by an instrument in writing signed by the party against which enforcement
of such amendment or waiver is sought. This Warrant shall be construed and
enforced in accordance with and governed by the laws of The Commonwealth of
Massachusetts. The headings in this Warrant are for purposes of reference only,
and shall not limit or otherwise affect any of the terms hereof. The invalidity
or unenforceability of any provision hereof shall in no way affect the validity
or

                                      -5-
<PAGE>

enforceability of any other provision.

                                      -6-
<PAGE>

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
a duly authorized officer as of January 26, 2001.

                                            SAFESCIENCE, INC.

                                            By:  /s/ Bradley Carver
                                                 -------------------------------
                                                 Bradley Carver, President

ACCEPTED AND AGREED:

WAYNE STATE UNIVERSITY

By: /s/ John L. Davis
   -----------------------------------------
Name:  John L. Davis
Title  Senior Vice President, Finance and Administration

Date:
     ---------------------------------------

                                      -7-
<PAGE>

                                    EXHIBIT 1

                               NOTICE OF EXERCISE

   (To be Executed by the Registered Holder in Order to Exercise the Warrant)

         1. The undersigned hereby irrevocably elects to purchase _____________
(________) shares of the Common Stock, $.01 par value per share, SafeScience,
Inc., pursuant to the Warrant Agreement between the Company and the undersigned
dated January 26, 2001 and according to the terms thereof, and herewith makes
payment of the Exercise Price of such shares in full.

         2. Such payment is hereby made in the amount of by wire transfer or by
certified or bank check.

         3. Please issue a certificate or certificates representing said shares
of Common Stock in the name of the undersigned or in such other name as is
specified below:

                                                   -----------------------------
                                                   (Name)

                                                   -----------------------------
                                                   (Address)

                                                   -----------------------------
                                                   Signature

Dated:
        ----------

                                                   -----------------------------
                                                   (Name)

                                                   -----------------------------
                                                   (Address)

                                                   -----------------------------
                                                   Signature

Dated:
        ----------

                                      -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}]]